We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for tolebrutinib (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
tolebrutinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adults
Therapeutic area
Neurology